Literature DB >> 10380062

Population-based investigations of drug relative clearance using nonlinear mixed-effect modelling from information generated during the routine clinical care of patients.

E Yukawa1.   

Abstract

Interpatient variability in drug disposition and response is a therapeutic premise, and thus evaluation and management of such variability are the basis for individualized pharmacotherapy. If the mathematical approach to determining drug doses were accurate and practical, the use of calculated doses could reduce the potential for toxicity and decrease the need for repetitious drug assays. The major strength of the population pharmacokinetics approach is that useful information can be extracted from sparse data collected during routine clinical care. Population pharmacokinetics can be defined as the study of the variability in serum drug concentrations between individuals when standard dosage regimens are administered. An approach to population pharmacokinetic data analysis has been implemented in the Nonlinear Mixed Effects Model (NONMEM) computer program. This report shows the feasibility of using a simple pharmacokinetic screen approach to estimate the population mean relative drug clearance and detecting drug-drug interaction by use of NONMEM. In clinical application of multiple trough screen or multiple peak screen, the variability of drug relative clearance within the population is assessed and a mathematical relationship between drug relative clearance and individual patient characteristics, such as age, body weight, gender, disease state or drug interaction with concomitant drug is derived. In this report I describe this approach and its application using several examples previously reported by us and others.

Entities:  

Mesh:

Year:  1999        PMID: 10380062     DOI: 10.1046/j.1365-2710.1999.00204.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  2 in total

1.  Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1.

Authors:  Jörn Lötsch; Sebastian Harder; Martin Stürmer; Hans-Wilhelm Doerr; Gerd Geisslinger; Schlomo Staszewski; Nils von Hentig
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

2.  Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences.

Authors:  Francis E Lotrich; Robert Bies; Matthew F Muldoon; Stephen B Manuck; Gwenn S Smith; Bruce G Pollock
Journal:  Psychopharmacology (Berl)       Date:  2004-09-09       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.